Related Experiment Video
Updated: Aug 17, 2025
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.1K
Preventing Teratogenicity in Women with Epilepsy
Michael O Kinney1,2, Phil E M Smith3, John J Craig1
1Department of Neurology, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom.
Seminars in Neurology
|December 13, 2022
Summary
Understanding the risks of antiseizure medications during pregnancy has improved, but knowledge gaps remain for newer drugs. Neurologists play a key role in informing women with epilepsy about these risks and treatment options.
Area of Science:
- Neurology
- Pharmacology
- Reproductive Health
Background:
- Significant advancements in understanding pregnancy challenges for women with epilepsy over 50 years.
- Emerging awareness of teratogenic risks linked to antiseizure medications (ASMs).
Purpose of the Study:
- To review current knowledge on teratogenic risks of ASMs in pregnancy.
- To highlight gaps in understanding risks, particularly for third-generation ASMs.
- To emphasize the evolving research focus beyond major congenital malformations to neurodevelopmental and behavioral outcomes.
Main Methods:
- Review of major pregnancy registers and scientific literature.
- Analysis of research trends concerning in utero exposure to ASMs.
- Consideration of public health and individual-level risk reduction strategies.
Main Results:
- Pregnancy registers have enhanced knowledge of teratogenic risks for common ASMs.
- Substantial knowledge gaps persist regarding risks of third-generation ASMs.
- Research now increasingly investigates neurodevelopmental and behavioral effects of in utero ASM exposure.
Conclusions:
- Public health initiatives can mitigate teratogenicity risks.
- Neurologists are crucial for individual-level risk reduction and patient education on ASM options during pregnancy.
- Continued research is vital to address knowledge gaps for all ASMs.
Related Concept Videos
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
518
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
518
01:24Epilepsy and Seizures: Overview
241
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
241
01:07Teratogenicity
2.6K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.6K
01:08Antiepileptic Drugs: Sodium Channel Blockers
776
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
776
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
399
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
399
01:14Antiepileptic Drugs: Glutamate Antagonists
473
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
473